{
  "ticker": "LLY",
  "target_date": "2025-10-15",
  "actual_date": "2025-10-15",
  "collected_at": "2025-12-08T12:24:35.774556",
  "price": {
    "open": 811.31,
    "high": 828.97,
    "low": 807.39,
    "close": 825.35791015625,
    "volume": 2355800,
    "change_1d_pct": 1.75,
    "change_7d_pct": -2.19,
    "change_30d_pct": 12.03
  },
  "technicals": {
    "rsi_14": 76.42,
    "sma_20": 791.54,
    "sma_50": 745.06,
    "macd": 24.066,
    "macd_signal": 23.304,
    "macd_histogram": 0.762,
    "bb_upper": 888.37,
    "bb_lower": 694.71,
    "price_vs_sma20_pct": 4.27,
    "price_vs_sma50_pct": 10.78,
    "volume_ratio": 0.61
  },
  "fundamentals": {
    "market_cap": 894152867840,
    "pe_ratio": 48.86967,
    "forward_pe": 44.017212,
    "price_to_book": 37.55384,
    "price_to_sales": 15.048062,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.3,
    "pct_from_52w_low": 59.9
  },
  "macro": {
    "spy": {
      "price": 665.17,
      "change_1d_pct": 0.44,
      "change_7d_pct": -0.59
    },
    "vix": {
      "level": 20.64,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.05
    },
    "dollar_index": {
      "level": 98.79
    },
    "gold": {
      "price": 4176.9
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
      "source": "Yahoo",
      "datetime": 1760564704,
      "summary": "Eli Lilly (LLY) concluded the recent trading session at $826.57, signifying a +1.75% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=65386244e883d8fcdb4da8894a806f7e992231c25e3417aee83fc7f6e9e0489f"
    },
    {
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "source": "MarketWatch",
      "datetime": 1760545860,
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=edacd68259ea9a9e8d146b2e23c960b64e99bfb3be35289623c22c0e2ec9d114"
    },
    {
      "headline": "Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition",
      "source": "SeekingAlpha",
      "datetime": 1760530976,
      "summary": "Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY stock following the latest data.",
      "url": "https://finnhub.io/api/news?id=11a4e2da9a2a24750ae447ed7afd4c08bfb961e75ba0f601e7de1aeaee6f88e3"
    },
    {
      "headline": "Eli Lilly Says Diabetes Drug Orforglipron Meets Key Goals in Two Phase 3 Trials",
      "source": "Yahoo",
      "datetime": 1760526940,
      "summary": "Eli Lilly (LLY) said Wednesday its experimental drug, orforglipron, met primary and all key secondar",
      "url": "https://finnhub.io/api/news?id=82e1f0b553dfcf133319ac28e7e4779bb03b81abcddd309990dd46c8118b4c81"
    },
    {
      "headline": "Lilly, battling skepticism, reinforces GLP-1 pill\u2019s case with new study data",
      "source": "Yahoo",
      "datetime": 1760526180,
      "summary": "Some Wall Street analysts have questioned orforglipron\u2019s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.",
      "url": "https://finnhub.io/api/news?id=e1492779ad9ab7ca94618ee81929ae3fd9a64c18cb23141f9549c138cf3efc54"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-10-14",
      "description": "xslF345X05/form4-10142025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000037/xslF345X05/form4-10142025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-10",
      "description": "xslF345X05/form4-10102025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000035/xslF345X05/form4-10102025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-09",
      "description": "xslF345X05/form4-10092025_041002.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000031/xslF345X05/form4-10092025_041002.xml"
    },
    {
      "form": "4",
      "date": "2025-10-08",
      "description": "xslF345X05/form4-10082025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000029/xslF345X05/form4-10082025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-07",
      "description": "xslF345X05/form4-10072025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000027/xslF345X05/form4-10072025_041001.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}